Soliton to be Featured on Yahoo Finance’s ‘The First Trade’ Show on May 13, 2019 to Discuss Cellulite Trial Results
Interview Will be Streamed Live at https://finance.yahoo.com during the 9:00AM EST Hour
Houston, TX – April 18, 2019 – Soliton, Inc., (NASDAQ: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced that its Executive Chairman, Walter Klemp, will give a live interview on Yahoo Finance on Monday, May 13, 2019.
As the Company has previously announced, data from its recently completed proof-of-concept clinical trial to study the safety and efficacy of a new version of its acoustic shockwave device for the treatment of moderate to severe cellulite will be presented to the scientific community at a national aesthetics conference, SCALE 2019 on May 11, 2019. This interview with Yahoo Finance will cover this new data and what it means for Soliton going forward.
Join our more than 200K fans here to follow the Company: https://soly-investors.com
“We’re pleased to announce that Yahoo Finance has selected us to be featured on their new live streaming network on ‘The First Trade’ on Monday, May 13, 2019 between 9AM – 10AM ET,” commented Walter Klemp, Executive Chairman of Soliton, Inc. “The focus will be to discuss our newly released cellulite clinical trial data. Yahoo Finance has a global audience of more than 90 million users each month and we’re excited to have the chance to show the world what the future may have in store for Soliton!”
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from MD Anderson. The Company’s first planned commercial product is designed to use rapid pulses of designed acoustic shockwaves in conjunction with existing lasers to accelerate the removal of unwanted tattoos (RAP device). In addition, higher energy versions of acoustic pulse devices are in early stages of development for potential stand-alone treatment of cellulite and other indications. Both products are investigational and are not available for sale in the United States.
For more information about the Company, please visit: http://www.soliton.com
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, viewership for ‘The First Trade’ on Yahoo Finance and the ability of Soliton’s acoustic shockwave device to reduce cellulite in the proof of concept clinical trial. These statements relate to future events, future expectations, plans and prospects. Although Soliton believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Soliton has attempted to identify forward-looking statements by terminology including ”believes,” ”estimates,” ”anticipates,” ”expects,” ”plans,” ”projects,” ”intends,” ”potential,” ”may,” ”could,” ”might,” ”will,” ”should,” ”approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under in our SEC filings, including under the heading “Item 1A. Risk Factors” in the Form 10-K for year ended December 31, 2018 we filed with the SEC and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. Soliton undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Joe Diaz & Robert Blum
Lytham Partners, LLC
SOURCE: Soliton, Inc.